Noonan syndrome (NS) is an autosomal dominant disorder, characterized by variable expressivity of clinical features such as: postnatal growth reduction, congenital heart disease, characteristic facial dysmorphisms and development delay. In ~75% of all NS cases, germline mutations involving RAS-MAPK signaling pathway genes (PTPN11, SOS1, RAF1, KRAS, NRAS, BRAF, SHOC2, MEK1, CBL) are causative.
We reported a case of 13-year-old girl [born at 36w by CS (BW 3250 g (~95°) , BL 48 cm (~75°)] referred for genetic counseling due to growth retardation, facial dysmorphisms, development delay and learning disability. After birth she presented frequent vomiting, with failure to thrive and at 5 months of age underwent surgery for intestinal malrotation. Because of short stature, Growth Hormone (GH) therapy have been introduced at age of 3yrs up to 11yrs. Negative molecular testing for PTPN11 and SOS1 genes, normal female karyotype and aCGH analysis were observed.
INTRODUCTION
Noonan syndrome (NS, OMIM 1635950) is a developmental disorder, characterized by variable expressivity, transmitted according to autosomal dominant manner (ROMANO et al., 2010) , with an incidence of 1/1000-2500 live births. The main clinical features are represented by postnatal growth retardation, congenital heart defect, characteristic facial dysmorphisms, multiple skeletal and ectodermal defects and development delay or cognitive impairment (TARTAGLIA et al., 2011) . Congenital heart defects are present in approximately 50-80% of affected individuals and include pulmonary valve stenosis, atrioventricular septal defects, aortic coarctation and hypertrophic cardiomyopathy (MARINO et al., 1999) .
NS is genetically heterogeneous and approximately 50% of all NS cases result from activating germline mutations in the PTPN11 gene, that acts as a key component in the RASmitogen activated protein kinases (MAPK) pathway. Mutations in other genes encoding proteins participating in the same signal transduction pathway have been found causative of NS and others clinically related disorders including cardio-facio-cutaneous (CFC), LEOPARD and Costello syndromes. All of these syndroms are identified as Neurocardiofacialcutaneous syndromes or RASopathies because they share both pathogenic mechanism and clinical features. Mutations in SOS1 gene account for approximately 10-13% of all cases of RAS-opathies; RAF1 3-17%; NRAS, BRAF, SHOC2, MEK1 and CBL < 1% (TARTAGLIA et al., 2002) . Less than 5% of patients with NS have mutations in KRAS gene and usually they have more severe form of the disorder (SCHUBERT et al., 2006; ZENKER et al., 2007) . NS is diagnosed by clinical features but today only 75% of all cases are confirmed by genetic testing (TIDYMAN et al., 2009) .
Case Report
A 13-year-old girl was referred to our unit for genetic counseling due to growth retardation, facial dysmorphisms, development delay and learning disability.
The proband was the only daughter of healthy and unrelated parents born at 36 th week of pregnancy by caesarian section due to premature rupture of the membranes. At birth, her weight was 3250 g (~95° percentile) and length was 48 cm (~75° percentile). In the first months of life, she showed feeding difficulties causing failure to thrive due to frequent vomiting and at the age of 5 months surgery for intestinal malrotation was performed. Because of short stature, she was treated by Growth Hormone (GH) from 3 until 11 years of age. She also had a history of development delay and learning problems and still requires learning support at school. Some genetic testing were done before genetic counseling performed by us, such as karyotype, which resulted in normal female karyotype (46,XX), normal results of array CGH and finally molecular testing performed for PTPN11 gene was negative. Objective examination of the patient revealed short stature with height and weight <3° percentile (H 138 cm; W 33 kg), puberal spurt delayed (no menarche at the age of 13 yrs), a distinctive facial appearance with hypertelorism, eyelids ptosis with downslanting palpebral fissures, low-set and posteriorly rotated ears, high arched palate, micrognathia, short and webbed neck, low hairline at the back of the neck, pectus excavatum, wide-set nipples with pectus excavatum, prominent scoliosis, relative joint hyperexensibility and bilateral pes planus as well reported in modificated table of clinical Features for NS from Tatraglia et al., (TATRAGLIA et al., 2011) with all signs presented in our patient (Table 1 Magnetic resonance imaging of the brain was normal apart from mild enlargement of leftlateral ventricle.
On the bassis of genetic counseling, objective examination, taking in consideration all possibilities of differential diagnosis and clinicians suspect (BUKVIC and ELLING, 2015; LATTANZI et al., 2012) on the basis of the best-practice we decided to perform further genetic tests. This procedure was deeply discussed with parents and colleges-pediatricians. However, as phenotype of our patient was suggestive for NS, even though genetic testing for PTPN11 gene was negative we proposed, as the first step, further mutational screening to evaluate the other genes involved in the RAS-MAPK signaling pathway which are correlated with NS. After obtaining informed consent from parents the KRAS, SHOC2, SOS1 and RAF1 genes were screened for mutations. This analysis allowed the identification of heterozygous missense mutation in exon 2 of KRAS gene (c.40G>A; p.Val14Ile). DISCUSSION KRAS gene is an essential player of the RAS-MAPK signal transduction pathway regulating several development processes such as cell growth, proliferation, migration, differentiation, survival and apoptosis. Besides heterozygous KRAS somatic mutations identified in about 30% of all human cancers (SCHUBBERT et al., 2007) , the heterozygous KRAS germline mutations have been also found in around 2-5% of reported cases of NS and < 5% Cardio-faciocutaneous syndrome (LEE et al., 2011; KRATZ et al., 2006) . KRAS somatic mutations are associated with malignancies due to RAS hyperactivation. On the other side, KRAS germline mutations are associated with NS and related disorders such as CFC (ZENKER et al., 2007) .
KRAS mutations are associated with a highly variable but generally severe phenotype of NS (CARTA et al. 2006) , including short stature, mental retardation, myeloproliferative disorder (juvenile myelomonocytic leukemia) (BADER-MEUNIER et al., 1997; TARTAGLIA et al., 2002) and heart defects. Up to 90% of affected individuals with NS present cardiac impairment with pulmonary valve stenosis, atrial/ventricle septal defect, patent ductus arteriosus and hypertrophic cardiomyopathy (HCM) which are diagnosed at early age (KASAKI et al., 2012) of 20% of NS patients with detected KRAS germline mutations. There are some reported cases describing specific KRAS mutations causative for severe phenotype of NS with rapidly evolving HCM and poor prognosis (NOSAN et al., 2013) .
However, our patient, up today, did not show any severe cardiac anomaly, apart mild mitral valve prolapse with no signs of cardiac impairment eventhouh the KRAS mutations c.40G>A (p.Val14Ile) were detected.
Furthermore, significant cognitive delay is more frequent in patients with NS which harboring KRAS mutations but clinically this situation usually is less severe when compared with patients affected by classical CFC (STARK et al., 2012) . Valuation of mental capability of our patient resulted in mild degree reduction of intellectual capacities. The patients with CFC syndrome more frequently demonstrated signs of central nervous system involvement such as ventricular enlargement, hydrocephalus, cerebral atrophy, agenesis of the corpus callosum and pachygyria respect to NS patients. Our patient reported a mild unilateral enlargement of left-lateral ventricle on brain imaging.
In conclusion, considering that the small number of reported NS patients harboring KRAS mutations the case reported by us, contributing on confirmation of wide phenotypic heterogeneity same as on the absence of a clear genotype-phenotype correlation. Despite the scientific literature (ZENKER et al., 2007; KRATZ et al., 2006) reported that germline KRAS mutations are generally associated with a severe phenotype of NS, our patient seems to have a mild clinical form and presenting some signs more frequent in other rasopathies. Considering this observation, we are wondering if it would be correct to speak about the fenotype between NS and CFC Syndrom, some kind of mixed RASopathy. Finally, the reported case emphasizes, the effectiveness of new techniques such as the Next Generation Sequencing technique, with the analysis of all known causative genes in a single experiment, useful to diagnose RAS-MAPK disorders considering presence of overlapping features of this pathological entities and involving of many disease-causing genes [i.e. NF1 gene for NFNS (BERTOLA et al., 2006) . On the other side it is necessary that these patients are carefully selected during Genetic Counseling and should be integrated as a part of multidisciplinary approach as well underligned by Bukvic and Margaglione (BUKVIC and MARGAGLIONE, 2013) . It is evident that with the surge of genetic tests and technologies, genetic counsellors are faced with the challenge of translating emerging scientific knowledge into practical information for patients and clinicians, Genetic counselors need to handle old, while rapidly assimilating new information, with the principal challenge which is to be up to date and updated (BUKVIC and MARGAGLIONE, 2013 Izvod Noonanov sindrome (NS) je autozomno dominantno oboljenje, sa varijabilnom ekspresivnošću kliničkih karakteristika, kao što su: redukcija postnatalnog rasta, kongenitalne srčane anomalije, karakteristični dizmorfizmi i zastoj u razvoju. U ~75% svih slučajeva NS, je moguće naći uzročnu germinalnu mutaciju u jednom od gena iz RAS-MAPK kaskade ("RAS-MAPK pathway genes": PTPN11, SOS1, RAF1, KRAS, NRAS, BRAF, SHOC2, MEK1, CBL) . Opisali smo slučaj trinaestogodišnje djevojčice [rodjene u 36 sedmici trudnoće -CR (Težina 3250 g (~95°), Dužina 48 cm (~75°)], koja se javila u našu ambulantu za Medicinsku Genetiku/Genetsko savjetovalište, zbog zastoja u rastu, dizmorfoloških znakova, zastoja u razvoju i učenju. Majka iznosi anamnestički podatak da je odmah nakon rodjenja, pacijentica povraćala te da je imala probleme u sukciji, dok je 5 mjeseci kasnije podvrgnuta hirurškoj intervenciji zbog obstrukcije crijeva. Terapija sa Hormonom Rasta (Growth Hormone -GH) je uvedena od treće godine starosti i provedena je sve do navršenih 11 godina. Naša pacijentica je već imala rezultate nekih gentskih testova kao što su: normalan ženski kariotip (46,XX), normalan nalaz arrayCGH i analiza PTPN11, SOS1 gena je rezultirala bez prisustva mutacija. Objektivni nalaz: Visina 138 cm, (<3°); Težina 33 kg, (<3°), bez menarche, hipertelorizam, ptoza gornjih očnih kapaka uz obostrano antimongoloidni položaj fissure palpebri, nisko usadjene i unatrag rotirane ušne školjke, visok svod nepca, mala vilica, kratak i zadebljan vrat, nisko postavljena linija kose, pectus excavatum, scolioza, hiperekstenzija zglobova, bilateralno pes planus i prolapse mitralne valvule ustanovljen prilikom US pregleda. Nakon pregleda fenotip pacijentice, po našem mišljnju je i dalje bio vrlo sugestivan za NS, zbog čega je odlučeno da se nastavi sa molekularnim genetskim testovima u svrhu potvrde navedene sumlje. Na taj način je evidentirano prisustvo missense mutacija (heterozigoza) u exonu 2 KRAS gena (c.40G>A; p.Val14Ile). Iako su mutacije KRAS gena obično povezane sa težim fenotipskim karakteristikama koje obuhvataju i promjene na srcu (npr. hipertrofična cardiomiopatia), ovi znakovi nisu bili prisutni kod naše pacijentice.
